Implementation of latent tuberculosis screening in HIV care centres: evaluation in a low tuberculosis incidence setting

被引:11
作者
Wyndham-Thomas, C. [1 ,2 ]
Schepers, K. [1 ]
Dirix, V. [2 ]
Mascart, F. [2 ,3 ]
Van Vooren, J. -P. [1 ]
Goffard, J. -C. [1 ]
机构
[1] Free Univ Brussels, Hop Erasme, Immunodeficiency Unit, 808 Route Lennik, B-1070 Brussels, Belgium
[2] Univ Libre Bruxelles, Lab Vaccinol & Mucosal Immunol, Brussels, Belgium
[3] Free Univ Brussels, Hop Erasme, Immunobiol Clin, 808 Route Lennik, B-1070 Brussels, Belgium
关键词
HIV/AIDS; prevention; screening programme; tuberculosis (TB); ISONIAZID PREVENTIVE THERAPY; RELEASE ASSAYS; SKIN-TEST; BARRIERS; ASSOCIATION; GUIDELINES; INFECTION; DIAGNOSIS;
D O I
10.1017/S0950268815001594
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The screening and treatment of latent tuberculosis infection (LTBI) to prevent active tuberculosis (TB) is recommended by the WHO in all HIV-infected patients. The aim of this study was to evaluate its implementation within Belgium's HIV care. A multiple-choice questionnaire was sent to 55 physicians working in the country's AIDS reference centres. Response rate reached 62%. Only 20% screened all their HIV-infected patients for LTBI. Screening methods used and their interpretation vary from one physician to another. The main barriers to the implementation of LTBI screening and treatment, as perceived by the participants, are lack of sensitivity of screening tools, risks associated with polypharmacy and toxicity of treatment. The poor coverage of LTBI screening reported here and the inconsistency in methods used raises concern. However, this was not unexpected as, in low-TB incidence countries, who, when and how to screen for LTBI remains unclear and published guidelines show important disparities. Recently, a targeted approach in which only HIV-infected patients at highest risk of TB are screened has been suggested. Such a strategy would limit unnecessary exposure to LTBI treatment. This methodology was approved by 80% of the participants and could therefore achieve greater coverage. Its clinical validation is still pending.
引用
收藏
页码:703 / 711
页数:9
相关论文
共 34 条
  • [1] Treatment of latent tuberculosis infection in HIV infected persons
    Akolo, Christopher
    Adetifa, Ifedayo
    Shepperd, Sasha
    Volmink, Jimmy
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [2] [Anonymous], TUB CLIN DIAGN MAN T
  • [3] [Anonymous], GLOB TUB REP 2013
  • [4] Balcells ME, 2006, EMERG INFECT DIS, V12, P744
  • [5] Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre
    Brassard, Paul
    Hottes, Travis Salway
    Lalonde, Richard G.
    Klein, Marina B.
    [J]. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2009, 20 (02) : 51 - 57
  • [6] Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis
    Cattamanchi, Adithya
    Smith, Rachel
    Steingart, Karen R.
    Metcalfe, John Z.
    Date, Anand
    Coleman, Courtney
    Marston, Barbara J.
    Huang, Laurence
    Hopewell, Philip C.
    Pai, Madhukar
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (03) : 230 - 238
  • [7] Tuberculin skin testing in patients with HIV infection: Limited benefit of reduced cutoff values
    Cobelens, Frank G.
    Egwaga, Saidi M.
    van Ginkel, Tessa
    Muwinge, Hemed
    Matee, Mecky I.
    Borgdorff, Martien W.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (05) : 634 - 639
  • [8] Cohn DL, 2000, AM J RESP CRIT CARE, V161, pS221
  • [9] EACS, GUID VERS 7 0
  • [10] The Next Therapeutic Challenge in HIV: Polypharmacy
    Edelman, E. Jennifer
    Gordon, Kirsha S.
    Glover, Janis
    McNicholl, Ian R.
    Fiellin, David A.
    Justice, Amy C.
    [J]. DRUGS & AGING, 2013, 30 (08) : 613 - 628